Table 1

Baseline characteristics of cancer cases and controls

VariablesOverall
N (%)		Control
N (%)		Case
N (%)		P value
 907317
Age at HIV (Q1–Q3)33.0 (26.0, 39.0)33.0 (26.0, 39.0)34.0 (29.0, 36.0)0.769
Age at cancer dx or sample collection (Q1–Q3)48.0 (43.0, 54.0)48.0 (43.0, 54.0)49.0 (44.0, 55.0)0.720
HIV years (Q1–Q3)15.0 (8.0, 20.0)14.0 (7.0, 21.0)16.0 (12.0, 20.0)0.975
CD4 (cells/mm3) at cancer dx or sample collection (Q1–Q3)450.5 (270.0, 690.0)448.0 (269.0, 690.0)471.0 (318.0, 629.0)0.902
CD4 nadir before cancer dx or sample collection (Q1–Q3)184.5 (86.0, 290.0)210.0 (89.0, 292.0)115.0 (83.0, 206.0)0.092
CD8 (cells/mm3) at cancer dx or sample collection (Q1–Q3)836.5 (577.0, 1112.0)817.0 (580.0, 1112.0)954.0 (563.0, 1110.0)0.7966
Absolute lymphocyte count (cells/mm3) at cancer dx or sample collection (Q1–Q3)1950.0 (1350.0, 2400.0)1800.0 (1350.0, 2400.0)2228.5 (1326.0, 2475.0)0.4241
Viral suppression years before cancer dx or sample collection
(Q1–Q3)		2.77 (1.74, 5.40)2.75 (1.84, 5.39)3.75 (1.53, 5.71)0.873
Time interval between sample collection to cancer diagnosed
(Q1–Q3, cases only)		1.0 (0.93, 1.13)
Race0.075
 Caucasian37 (41.1)29 (39.7)8 (47.1)
 African–American37 (41.1)28 (38.4)9 (52.9)
 Other16 (17.8)16 (21.9)0 (0.0)
Gender0.990
 Male86 (95.6)69 (94.5)17 (100.0)
 Female4 (4.4)4 (5.5)0 (0.0)
Protease-inhibitor based ART0.687
 No41 (45.6)34 (46.6)7 (41.2)
 Yes49 (54.4)39 (53.4)10 (58.8)
ART Drug Classes0.176
 Non-nucleoside reverse transcriptase inhibitor35 (38.9)31 (42.5)4 (23.5)
 Boosted protease inhibitor36 (40.0)28 (38.4)8 (47.1)
 Unboosted protease inhibitor13 (14.4)11 (15.1)2 (11.8)
 Integrase inhibitor2 (2.2)1 (1.4)1 (5.9)
 Other4 (4.4)2 (2.7)2 (11.8)
Cancer type
 Non-small cell lung cancer4 (23.5)
 Non-Hodgkin's lymphoma4 (23.5)
 HPV-related cancer9 (52.9)

  • HPV (Human Papilloma Virus)

  • ART, antiretroviral therapy .